Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)

NCT07711002 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

1330

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Interventions

DRUG: Saruparib
OTHER: Placebo
DRUG: Enzalutamide
DRUG: Darolutamide
DRUG: Abiraterone

Sponsor

AstraZeneca